Neonatal abstinence syndrome is defined by signs and symptoms of withdrawal that infants
develop after intrauterine maternal drug exposure. All infants with documented in utero …

Neonatal abstinence syndrome (NAS) is suffered by infants withdrawing from substances on
which they have become physically dependent after in utero exposure. They may require …

Substance use among pregnant women is a major public health issue. Both prescription
opioid use and illicit opioid abuse have increased dramatically in recent years. Prolonged in …

Objective: To systematically and critically analyse and summarise the published evidence
for the rational choice of pharmacologic treatment of the neonatal abstinence syndrome …

Neonatal abstinence syndrome (NAS) comprises a constellation of drug-withdrawal
symptoms that result from chronic intrauterine exposure to a variety of substances, including …

Neonatal abstinence syndrome (NAS) is defined as a constellation of symptoms typically
observed in the newborn of a mother who has received opioids and other medications for a …

Background: The evaluation and management of infants with neonatal abstinence syndrome
(NAS), the constellation of opioid withdrawal specific to newborns, have received renewed …

Neonatal abstinence syndrome (NAS) is a result of the sudden discontinuation of fetal
exposure to substances that were used or abused by the mother during pregnancy …

Neonates exposed prenatally to opioids will often develop a collection of withdrawal signs
known as neonatal abstinence syndrome (NAS). The incidence of NAS has substantially …

Recent rise in rates of opiate replacement therapy among pregnant women have resulted in
increasing number of infants requiring treatment for neonatal abstinence syndrome (NAS) …